Androgen receptor reactivation in castration-resistant prostate cancer: mechanisms, epigenetic adaptation, and therapeutic vulnerabilities - Scorecard - MDSpire

Androgen receptor reactivation in castration-resistant prostate cancer: mechanisms, epigenetic adaptation, and therapeutic vulnerabilities

  • By

  • Juntao Guo

  • Ke Wu

  • Zheng Ma

  • Shuai Guo

  • Fei Wang

  • Lingxiang Lu

  • May 21, 2026

  • 0 min

Share

Clinical Scorecard: Reactivation of Androgen Receptors in Castration-Resistant Prostate Cancer: Mechanisms, Epigenetic Changes, and Treatment Vulnerabilities

At a Glance

CategoryDetail
Condition
Key MechanismsAR amplification, overexpression, ligand-binding domain mutations, splice variants, intratumoral androgen synthesis, bypass signaling, altered AR co-regulators, epigenetic changes.
Target Population
Care Setting

Key Highlights

  • CRPC is characterized by persistent AR signaling despite androgen deprivation.
  • AR reactivation involves multiple overlapping mechanisms that promote treatment resistance.
  • Epigenetic changes play a crucial role in maintaining AR-dependent transcription.
  • Therapeutic strategies include AR degraders, PARP inhibitors, epigenetic therapies targeting EZH2, BET proteins, p300/CBP, LSD1, or HDACs.
  • Biomarker-guided treatment may enhance therapy selection for CRPC patients.

Guideline-Based Recommendations

Diagnosis

  • Assess AR signaling status and resistance mechanisms in CRPC.

Management

  • Utilize next-generation AR pathway inhibitors, consider combination therapies, and include epigenetic therapies.

Monitoring & Follow-up

  • Regularly evaluate treatment response, resistance markers, and changes in AR signaling pathways.

Risks

  • Monitor for potential side effects of AR-targeted therapies and resistance development.

Patient & Prescribing Data

Patients with advanced prostate cancer who have progressed on standard therapies.

Consider AR-targeted therapies based on individual resistance mechanisms and biomarker profiles.

Clinical Best Practices

  • Incorporate genetic and epigenetic profiling in treatment planning.
  • Monitor for changes in AR signaling pathways during therapy.
  • Consider combination therapies targeting multiple resistance mechanisms.

Related Resources & Content

Original Source(s)

Related Content